• Eugene Milshteyn, Harry Griffin, Yi Shuen Chang, Ibraheem Shaikh, Tim Sprenger, Stefan Skare, Christopher J Maclellan, and Salil Soman.
• GE HealthCare, Boston, Massachusetts, USA.
• J Neuroimaging. 2025 Jan 1; 35 (1): e13248e13248.

Background And PurposeNeuromix is a fast, motion robust multi-contrast sequence capable of providing all diagnostic contrasts in ∼3.5 minutes. However, more evaluation is needed across the various contrasts compared to gold standard, optimized sequences routinely used in the clinic. The goal of this study was to prospectively determine how NeuroMix performs in the clinical setting compared to routine clinical MRI.MethodsNeuroMix and routine clinical MRI sequences were acquired on a 3 Tesla clinical scanner for 39 patients clinically indicated for brain MRI. Three radiologists were asked to assess the diagnostic confidence of NeuroMix compared to the routine MRI using a series of questions. Signal-to-noise and contrast-to-noise ratios (SNR and CNR) were assessed for NeuroMix. Fleiss' free-marginal multirater kappa was calculated for the qualitative assessment performed by the radiologists.ResultsRadiologists were comfortable substituting or reading some of the NeuroMix sequences in place of the corresponding conventional sequence for some contrasts, including diffusion-weighted imaging, single-shot T2, and susceptibility-weighted imaging. The image quality, SNR, and CNR allowed the radiologists to visualize anatomy and pathology on NeuroMix images. There was no significant difference between coefficient of variation for the apparent diffusion coefficient maps (p = .084).ConclusionsAnalysis revealed both positives and some pitfalls of NeuroMix. However, these results indicate Neuromix as having the capability to be a backup sequence in case artifacts are present in routine sequences, or potentially a replacement for some contrasts altogether.© 2024 American Society of Neuroimaging.

26 keywords...

hide…